Product name: Terminolic acid
Synonym name: 2α,6β,23-trihydroxyl oleanolic acid；(2α,3β,4α,6β)-2,3,6,23-Tetrahydroxyolean-12-en-28-oic acid
Catalogue No.: BP4376
Cas No.: 564-13-6
Formula: C30H48O6
Mol Weight: 504.708
Botanical Source:
Type of Compound:
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
HPLC of Terminolic acid
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Centella asiatica acid B glycoside (Terminolic acid, CAS No.: 564-13-6) is a natural product of the pentacyclic triterpene glycoside, mainly isolated from the plant Combretum racemosum. As a natural compound with significant antibacterial and anti-inflammatory activity, centella acid B aglycon has attracted widespread attention in the field of natural product pharmacology. In recent years, with in-depth research into its biological activity and mechanism of action, centella acid B aglycone has shown promising application potential in antibacterial, anti-inflammatory, and tumor treatment, especially in colon cancer and skin repair fields. This paper aims to systematically review the chemical structure, physicochemical properties, plant origin, pharmacological activity, mechanism of action, druggability evaluation, and clinical application prospects of centella acid B aglycon, aiming to provide a theoretical foundation and reference for subsequent research and drug development.
Centella acid B glycoside belongs to the pentacyclic triterpene glycoside compound, with a molecular formula of C_30H_48O_7 and a molecular weight of 504.7080. Its structural core is a typical pentacyclic triterpene skeleton, connected to glycoside sections, giving it unique physicochemical properties. The LogP value of centella acid B aglycone was 3.7517, indicating moderate lipid solubility, which facilitates membrane penetration and bioavailability. Its topological pole surface area (TPSA) is 118.2200, indicating that the molecule has certain polarity, which may affect its binding ability to biological targets and its distribution in vivo. Low water solubility (0.0320 mg/mL) suggests limited solubility in the aqueous phase, posing certain challenges to formulation processes. Centella acid B glycoside is less likely to cross the blood-brain barrier, reducing the risk of central nervous system side effects. Additionally, the hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity, while the Ames test result was 0.0, indicating no significant mutagenicity and meeting safety requirements.
Centella asiatica B glycoside was first isolated from Combretum racemosum, a plant belonging to the Combretaceae family, widely distributed in tropical and subtropical regions. Traditionally, Combretum racemosum has been used in folk medicine, possessing antibacterial, anti-inflammatory, and wound healing effects. The extraction of Asiatica glycoside B aglycone usually uses organic solvent extraction combined with column chromatography separation technology. The specific steps include:
In recent years, ultrasound-assisted extraction and microwave-assisted extraction techniques have also been applied to the extraction of centella asiatica B aglycon, improving extraction efficiency and purity.
The pharmacological activities of Asiatica glycoside B aglycine mainly include antibacterial, anti-inflammatory, and antitumor effects. The following describes the main research advances.
Centella asiatica B aglycon exhibits significant inhibitory effects on various pathogenic bacteria, especially common Gram-positive and Gram-negative strains such as Staphylococcus aureus, Escherichia coli, and Enterococcus faecalis. Its minimum inhibitory concentration (MIC) ranges from 64 to 256 μg/mL, demonstrating moderate antibacterial activity. The antibacterial mechanism may involve inhibition of bacterial cell wall synthesis and destruction of cell membranes, but the specific molecular mechanisms require further elucidation.
Asiatica glycoside B glycogen exerts anti-inflammatory effects by regulating pro-inflammatory cytokines. Studies have shown that it can bind to and inhibit the active sites of IL-1β and IL-6 receptors, significantly reducing the expression of the pro-inflammatory cytokine IL-8, thereby alleviating inflammatory responses. This mechanism suggests that Asiatica B glycoside may exert anti-inflammatory effects by interfering with inflammatory signaling pathways and inhibiting the release of inflammatory mediators.
Asiatica B aglycoside demonstrates potential antitumor effects in colon cancer research. In vitro cell experiments have shown that it can inhibit the proliferation and migration of colon cancer cells and induce apoptosis. Its anti-tumor mechanism may be related to regulating the inflammatory microenvironment, suppressing the expression of pro-tumor factors, and interfering with cellular signaling pathways. Although related research is still in its early stages, the potential of centella acid B aglycone as a natural anti-tumor candidate is worth in-depth exploration.
Research on Asiatica glycoside B glycoside in the field of skin repair is increasing. By modulating various targets related to skin reconstruction, including matrix metalloproteinases (MMP1, MMP2, MMP9), epidermal growth factor receptors (EGFR), fibroblast growth factor 2 (FGF2), transforming growth factor β1 (TGFB1), collagen proteins (COL3A1, COL4A1), and integrin β1 (ITGB1), it promotes extracellular matrix remodeling and skin tissue repair. This mechanism of action provides a theoretical basis for the application of Asiatica glycoside B aglycon in wound healing and skin disease treatment.
The biological activity of centella acid B aglycone mainly occurs through interactions with multiple molecular targets.
Centella acid B aglycon binds to the active sites of pro-inflammatory cytokines IL-1β and IL-6 receptors, blocking their signal transduction and inhibiting the release of downstream inflammatory mediators. IL-1β and IL-6 are key mediators in inflammatory responses, and their overexpression is closely linked to various inflammatory diseases. The binding and inhibitory effect of Asiatica glycoside B glycogen effectively reduces IL-8 production. As a chemokine, IL-8 participates in the recruitment and activation of inflammatory cells, and its reduction helps alleviate inflammatory damage.
Centella Asiatic glycoside B aglycoside exhibits inhibitory effects on bacteria such as Staphylococcus aureus, Escherichia coli, and Enterococcus faecalis. Its antibacterial mechanisms are suspected to include damaging bacterial cell membrane integrity, interfering with cell wall synthesis, and inhibiting key bacterial enzyme activities, thereby inhibiting bacterial growth. The specific targets are not yet fully understood, and further analysis is needed in the future combined with molecular docking and proteomics techniques.
Centella acid B glycoside promotes extracellular matrix (ECM) remodeling and cell proliferation and migration by regulating various protein targets related to skin repair. MMPs (MMP1, MMP2, MMP9) participate in ECM degradation and remodeling, and centella asiatica B aglycosides maintain dynamic ECM balance by regulating their expression. EGFR and FGF2 promote the proliferation of keratinocytes and fibroblasts; TGFB1 regulates fibrosis and collagen synthesis; COL3A1 and COL4A1 are the main components of collagen; ITGB1 mediates cell adhesion and signal transduction between cells and the matrix. Centella asiatin B aglycone promotes skin tissue repair and regeneration by coordinating these targets.
Centella acid B aglycone exhibits proliferation-inhibiting and apoptosis-inducing effects in colon cancer cells, possibly by regulating the inflammatory microenvironment and signaling pathways. Its ability to inhibit pro-inflammatory cytokines helps slow tumor-related inflammation and suppress tumor cell survival and migration. Specific molecular mechanisms involve the regulation of inflammatory and tumor-related signaling pathways such as NF-κB and STAT3, which require further experimental validation.
The druggability parameters of Asiatica B glycolycon indicate that it has good potential for drug development. The molecular weight of 504.7 meets the basic requirements of the Lipinski rule, with a LogP of 3.75, indicating moderate lipid solubility and favorable penetration of cell membranes. A TPSA value of 118.22 suggests the molecule has certain polarity, which may limit oral absorption but also facilitates target binding. Low water solubility suggests that formulation design should use solubilization or nanocarrier technologies to improve bioavailability.
The blood-brain barrier has low permeability, reducing the risk of central nervous system side effects. hERG channel inhibition was negative, indicating a lower risk of cardiotoxicity. The Ames test is non-mutagenic and has good safety. Current data still lack systematic pharmacokinetic (PK) studies. Future studies on in vivo absorption, distribution, metabolism, excretion (ADME), and toxicology are needed to clarify in vivo behavior and safe dose ranges.
Centella asiatica B-glycoside, as a versatile natural product, has broad clinical application potential.
Antimicrobial drug development: Facing antibiotic resistance issues, Asiaticaside B aglycoside exhibits inhibitory effects on various bacteria and can serve as a lead compound for new antimicrobial drugs or in combination with existing antibiotics to enhance antibacterial effects.
Anti-inflammatory therapy: By regulating key inflammatory factors such as IL-1β, IL-6, and IL-8, Centella Asiaticoside B aglycon holds promise for treatment of inflammatory diseases such as chronic inflammation, rheumatic diseases, and skin inflammation.
Tumor adjuvant therapy: The antitumor activity of Centella Asiatic B aglycoside in colon cancer cells suggests its potential as an adjunct drug in tumor treatment, especially in regulating the tumor microenvironment and inhibiting inflammation-related tumor progression.
Skin repair and regeneration: Asiatica B glycoside regulates various skin repair targets, suitable for wound healing, burns, and skin disease treatment. In the future, it can be developed as a topical formulation or functional skincare product.
Although the pharmacological effects of Asiatica glycoside B glycoside are preliminarily clear, its clinical translation still faces many challenges, such as drug stability, in vivo metabolic characteristics, and formulation development. In the future, it is necessary to strengthen pharmacokinetics, safety evaluation, and preclinical animal model research to promote clinical application.
Centella asiatica B-glycoside, a natural product of pentacyclic triterpene glycosides, exhibits multiple pharmacological activities, especially with broad research and application prospects in antibacterial, anti-inflammatory, anti-tumor, and skin repair fields. Its unique mechanism of action and good safety provide strong support for new drug development. In the future, molecular mechanism research, pharmacokinetics, and preclinical evaluation should be strengthened, combined with modern drug formulation technologies, to promote the clinical transformation of Centella Asiatica glycoside B aglycon, providing new natural drug candidates for the treatment of related diseases.
